Reproducibility of Fibrinolytic Response to Venous Occlusion in Healthy Subjects

Summary

Fibrinolytic response to venous occlusion is used to assess the efficiency of the fibrinolytic system. Reproducibility of fibrinolytic variables after 20 min upper arm venous occlusion was investigated in 40 apparently healthy subjects tested twice in a period of 11-23 (mean 15) days. Resting and post-venous occlusion euglobulin clot lysis time, tissue-type plasminogen activator (t-PA) activity, t-PA antigen, plasminogen activator inhibitor (PAI) activity and plasminogen activator inhibitor type 1 (PAI-1) antigen determined on the two occasions did not differ significantly. Positive correlation coefficients for variables before (r=0.43-0.74, all p<0.01) and after venous occlusion (r=0.07-0.66) indicated low to moderate associations between repeated measurements. Differences between repeated measurements relative to the initial measurement were greater after venous occlusion than before venous occlusion and were for euglobulin activity 41 (0-826)%, t-PA activity 27 (2-398)%, and for t-PA antigen 27 (0-179)% (medians and ranges). Poor responses were defined by the lowest (euglobulin activity, t-PA activity and t-PA antigen) or the highest (PAI activity) fifth percentile of the distribution. Almost no agreement between poor responses was observed: poor responses at the first occasion were not determined in the same subjects when re-examined after two weeks. It was concluded that due to relatively low reproducibility of the variables measured after venous occlusion the test needs improvement in order to be potentially clinically useful.

• References

• 1 Robertson BR, Pandolfi M, Nilsson IM. “Fibrinolytic capacity” in healthy volunteers as estimated from effect of venous occlusion of arms. Acta Chir Scand 1972; 138: 429-436
• 2 Samama M. Hypofibrinolysis and venous thrombosis. In Thrombosis: an update. Neri Serneri GG, Gensini GF, Abbate R, Prisco D. eds. Scientific Press; Florence: 1992. pp 165-181
• 3 Jespersen J. The venous occlusion test in fibrinolysis assays. In ECAT assay procedures. A manual of laboratory techniques. Jespersen J, Bertina RM, Haverkate F. eds. Kluwer Academic Publishers; Dordrecht-Boston- London: 1992. pp 213-216
• 4 Holvoet P, Boes J, Collen D. Measurement of free, one-chain tissue-type plasminogen activator in human plasma with an enzyme-linked immunosorbent assay based on an active site-specific murine monoclonal antibody. Blood 1987; 69: 284-289
• 5 Booth NA, Walker E, Maughan R, Bennett B. Plasminogen activator in normal subjects after exercise and venous occlusion: t-A circulates as complexes with Cl-inhibitor and PAI-1. Blood 1987; 69: 1600-1604
• 6 Keber D, Blinc A, Fettich J. Increase of tissue plasminogen activator in limbs during venous occlusion: A simple haemodynamic model. Thromb Haemost 1990; 64: 433-437
• 7 Nilsson IM, Ljungner H, Tengbom L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J 1985; 290: 1453-1456
• 8 Wiman B, Ljungberg B, Chmielewska J, Urdén G, Blombäck M, Johnsson H. The role of the fibrinolytic system in deep vein thrombosis. J Lab Clin Med 1985; 105: 265-270
• 9 Juhan-Vague I, Valadier J, Alessi MC, Aillaud MF, Ansaldi J, Philip-Joet C, Holvoet P, Serradimigni A, Collen D. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost 1987; 57: 67-72
• 10 Engesser L, Brommer EJ P, Kluft C. Briët. Elevated plasminogen activator inhibitor (PAI), a cause of thrombophilia? - A study in 203 patients with familial or sporadic venous thrombophilia. Thromb Haemost 1989; 62: 673-680
• 11 de Bart AC W, Hennis BC, Havelaar AC, Kluft C. Variability in information from a single venapuncture in healthy volunteers: Analysis of the haemostatic variables fibrinogen, plasminogen activator inhibitor (PAI) activity and histidine-rich glycoprotein (HRG). Fibrinolysis 1992; 6 suppl (Suppl. 03) 81-82
• 12 Isacson S, Nilsson IM. Defective fibrinolysis in blood and vein walls in recurrent “idiopathic” venous thrombosis. Acta Chir Scand 1972; 138: 313-319
• 13 Korninger C, Lechner K, Niessner H, Gossinger H, Kundi M. Impaired fibrinolytic capacity predisposes for recurrence of venous thrombosis. Thromb Haemost 1984; 52: 127-130
• 14 Tengborn L. Laboratory investigation of fibrinolytic and other haemostatic risk factors in patients with venous thromboembolism. In Clinical aspects of fibrinolysis. Nilsson TK, Boman K, Jansson JH. eds Almqvist & Wiksell International; Stockholm: 1991. pp 67-84
• 15 Keber D, Stegnar M. Exhaustion of arm fibrinolytic potential after repeated venous occlusion and local exercise. Thromb Res 1982; 28: 693-704
• 16 Epstein O, Perkin GD, de Bono DP, Cookson J. Clinical Examination. Mosby, London-St; Louis-Baltimore-Boston-Chicago-Philadelphia-Sydney- Toronto: 1992. pp 7.27-7.29
• 17 Stevens JD, Sanfelippo MJ. Evaluation of three methods for plasma fibrinogen determination. Amer J Clin Patho 1973; 60: 182-187
• 18 Buckell M. The effect of citrate on euglobulin methods of estimating fibrinolytic activity. J Clin Path 1958; 11: 403-405
• 19 Rånby M, Bergsdorf N, Nilsson T, Mellbring G, Winblad B, Bucht G. Age dependence of tissue plasminogen activator concentrations in plasma studied by an improved enzyme linked immunosorbent assay. Clin Chem 1986; 32: 2160-2165
• 20 Verheijen JH, Chang GT G, Kluft C. Evidence for the occurence of a fastacting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemost 1984; 51: 392-395
• 21 Keber D, Stegnar M, Kluft C. Different tissue plasminogen activator release in the arm and leg during venous occlusion is equalized after DDAVP infusion. Thromb Haemost 1990; 63: 72-75
• 22 Stegnar M, Peternel P, Keber D, Vene N. Poor fibrinolytic response to venous occlusion by different criteria in patients with deep vein thrombosis. Thromb Res 1991; 64: 445-453
• 23 Declerck PJ, Alessi MC, Verstreken M, Kruithof EK O, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 71: 220-225
• 24 Rånby M, Norrman B, Wallén P. A sensitive assay for tissue plasminogen activator. Thromb Res 1982; 27: 743-749
• 25 Keber D. On the use of different correction factors for hemoconcentration. Thromb Haemost 1983; 49: 238
• 26 Stegnar M, Pentek M. Fibrinolytic response to venous occlusion in healthy subjects: Relationship to age, gender, body weight, blood lipids and insulin. Thromb Res 1993; 69: 81-92
• 27 Declerk PJ, Verstreken M, Collen D. Mesurement of different forms of plasminogen activator inhibitor 1 (PAI-1) using various monoclonal antibody-based enzyme-linked immunosorbent assays. Fibrinolysis 1990; (Suppl. 04) suppl 2: 132-133
• 28 Kluft C. Cl-inactivator-resistant fibrinolytic activity in plasma euglobulin fractions: its relation to vascular activator in blood and its role in euglobulin fibrinolysis. Throm Res 1978; 13: 135-151
• 29 Malm J, Laurell M, Nilsson IM, Dahlbäck B. Thromboembolic disease - Critical evaluation of laboratory investigation. Thromb Haemost 1992; 68: 7-13
• 30 Sultan Y, Harris A, Strauch G, Venot A. De Lauture. A dynamic test to investigate potential tissue plasminogen activator activity. Comparison of de- amino-8-D-argininevasopressin with venous occlusion in normal subjects and patients J Lab Clin Med 1988; 111: 645-653
• 31 Stegnar M, Keber I, Keber D, Peternel P. Fibrinolytic potential in healthy men and in patients with thrombotic disease. Period Biol 1987; 89: 95-103
• 32 Marckmann P, Sandström. Jespersen J. The variability of and associations between measures of blood coagulation, fibrinolysis and blood lipids. Atherosclerosis 1992; 96: 235-244